Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANG2010
- Development stage
- Preclinical
- Lead developer
- Angiochem
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
ANG2010 is a preclinical peptide-drug conjugate (PDC) developed by Angiochem for the treatment of pain. It utilizes Angiochem's proprietary EPiC (Engineered Peptide Compounds) platform, specifically the Angiopep-2 peptide, to facilitate the transport of morphine-6-glucuronide (M6G) across the blood-brain barrier (BBB). M6G is a potent analgesic metabolite of morphine that acts primarily on mu-opioid receptors. By leveraging receptor-mediated transcytosis via the low-density lipoprotein receptor-related protein 1 (LRP1), ANG2010 is designed to enhance the delivery of the opioid payload into the central nervous system, potentially offering potent analgesia with reduced peripheral side effects.
02
Targets
LRP1 (Prolow-density lipoprotein receptor-related protein 1)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on ANG2010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANG2010.